Alexandria Pharmaceuticals results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit41.25 millionEGP · +24.1% vs the same period a year earlier
Total assets917 millionEGP · +3.6% vs the same period a year earlier
Shareholders' equity647 millionEGP · +17.1% vs the same period a year earlier
Operating cash flow-16.54 millionEGP · −144.4% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q1 2023 was about 41.25 million EGP, up +24.1% from 33.23 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 917 million EGP, and shareholders' equity about 647 million EGP.
- Operating cash flow for Q1 2023 was negative at 16.54 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit41.25 million33.23 million+24.1%
Gross profit89.92 million74.17 million+21.2%
Total assets917 million885 million+3.6%
Total liabilities270 million332 million−18.8%
Shareholders' equity647 million553 million+17.1%
Total liabilities and equity917 million885 million+3.6%
Operating cash flow-16.54 million37.25 million−144.4%
Investing cash flow-36.86 million-14.38 million−156.3%
Financing cash flow-393 thousand-289 thousand−36.0%
Net change in cash-53.8 million22.57 million−338.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy